Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
45
ACIU Quote, Financials, Valuation and Earnings
Last price:
$2.90
Seasonality move
:
-5.85%
Day range:
$2.72 - $2.90
52-week range:
$1.43 - $4.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
56.16x
P/B ratio:
3.69x
Volume:
137.9K
Avg. volume:
316K
1-year change:
-10%
Market cap:
$289.7M
Revenue:
$31M
EPS (TTM):
-$0.84
Analysts' Opinion
-
Consensus RatingAC Immune SA has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.61, AC Immune SA has an estimated upside of 235.06% from its current price of $2.88.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.88 representing 100% downside risk from its current price of $2.88.
Fair Value
-
According to the consensus of 3 analysts, AC Immune SA has 235.06% upside to fair value with a price target of $9.61 per share.
ACIU vs. S&P 500
-
Over the past 5 trading days, AC Immune SA has underperformed the S&P 500 by -1.82% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AC Immune SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AC Immune SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter AC Immune SA reported revenues of $1.2M.
Earnings Growth
-
AC Immune SA earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter AC Immune SA reported earnings per share of -$0.20.
Enterprise value:
159.3M
EV / Invested capital:
1.89x
Price / LTM sales:
56.16x
EV / EBIT:
--
EV / Revenue:
30.91x
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-2.61x
Price / Operating cash flow:
4.73x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-34.2%
Net Income Margin (TTM):
-1642.97%
Return On Equity:
-75.88%
Return On Invested Capital:
-72.31%
Operating Margin:
-1671.93%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1K | $46.9M | $5.2M | $29.4M | $1.2M | |
| Gross Profit | -$1.8M | -$635.9K | -- | -- | -- | |
| Operating Income | -$76.5M | -$42.3M | -$85.9M | $8.4M | -$19.6M | |
| EBITDA | -$74.1M | -$39.8M | -$83.1M | $9M | -$18.9M | |
| Diluted EPS | -$0.88 | -$0.45 | -$0.84 | $0.06 | -$0.20 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $209.4M | $150M | $94.2M | $222.4M | $143M | |
| Total Assets | $218M | $208.8M | $156.3M | $289.5M | $215.7M | |
| Current Liabilities | $15.2M | $13.8M | $12.8M | $119.7M | $123.5M | |
| Total Liabilities | $25.9M | $15.8M | $18.9M | $135.2M | $137.2M | |
| Total Equity | $192.1M | $193.1M | $137.4M | $154.3M | $78.5M | |
| Total Debt | $2.8M | $2.5M | $2.6M | $3.7M | $5.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$68.3M | $51.1M | -$60M | -$12.7M | -$24.3M | |
| Cash From Investing | $53.1M | -$91.1M | $56.5M | -$7.2M | $26.8M | |
| Cash From Financing | $2.4M | $45.2M | -$1.2M | -$236.1K | -$337K | |
| Free Cash Flow | -$69M | $50.4M | -$61.1M | -$12.9M | -$24.4M | |
ACIU
Sector
Market Cap
$289.7M
$28.8M
Price % of 52-Week High
72%
51.13%
Dividend Yield
0%
0%
Shareholder Yield
-0.15%
-1.32%
1-Year Price Total Return
-10%
-20.64%
Beta (5-Year)
1.602
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.89
200-day SMA
Buy
Level
$2.32
Bollinger Bands (100)
Buy
Level
2.19 - 3.23
Chaikin Money Flow
Sell
Level
-141M
20-day SMA
Sell
Level
$3.08
Relative Strength Index (RSI14)
Sell
Level
44.40
ADX Line
Sell
Level
20.84
Williams %R
Neutral
Level
-71.0526
50-day SMA
Sell
Level
$3.17
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
242.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.271)
Sell
CA Score
(Annual)
Level (-0.7874)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.2833)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Stock Forecast FAQ
In the current month, ACIU has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACIU average analyst price target in the past 3 months is $9.61.
-
Where Will AC Immune SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that AC Immune SA share price will rise to $9.61 per share over the next 12 months.
-
What Do Analysts Say About AC Immune SA?
Analysts are divided on their view about AC Immune SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AC Immune SA is a Sell and believe this share price will drop from its current level to $7.88.
-
What Is AC Immune SA's Price Target?
The price target for AC Immune SA over the next 1-year time period is forecast to be $9.61 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACIU A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AC Immune SA is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACIU?
You can purchase shares of AC Immune SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AC Immune SA shares.
-
What Is The AC Immune SA Share Price Today?
AC Immune SA was last trading at $2.90 per share. This represents the most recent stock quote for AC Immune SA. Yesterday, AC Immune SA closed at $2.88 per share.
-
How To Buy AC Immune SA Stock Online?
In order to purchase AC Immune SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ACIU Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACIU
Sector
P/E ratio
--
23.71x
PEG ratio
-0.04x
-0.01x
P/B ratio
3.69x
1.84x
Price / LTM sales
56.16x
1.60x
Growth Metrics
ACIU
Sector
Revenue growth
-96.01%
4.85%
Earnings growth
-411.75%
11.15%
Revenue (5-year growth)
-22.53%
6.45%
Earnings forecast
-$0.22
-$0.20
Profitability
ACIU
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-72.31%
-30.98%
Return on assets
-34.2%
-27.62%
Return on equity
-75.88%
-36.69%
Earnings Date
Last Earnings Date
Nov
4
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
3
Balance Sheet
ACIU
Sector
Total cash
$136.3M
$27.2M
Short term investments
$143M
$25.7M
Total assets
$254.8M
$79.7M
Long term debt
$5.9M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
